{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:30:17Z","timestamp":1782844217930,"version":"3.54.5"},"reference-count":146,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Cardiovascular disease (CVD) is a leading complication after liver transplantation and has a significant impact on patients\u2019 outcomes posttransplant. The major risk factors for post\u2013liver transplant CVD are age, preexisting CVD, nonalcoholic fatty liver disease, chronic kidney disease, and metabolic syndrome. This review explores the contemporary strategies and approaches to minimizing cardiometabolic disease burden in liver transplant recipients. We highlight areas for potential intervention to reduce the mortality of patients with metabolic syndrome and CVD after liver transplantation.<\/jats:p>","DOI":"10.1097\/tp.0000000000004875","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T18:00:42Z","timestamp":1701972042000},"page":"1689-1699","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation"],"prefix":"10.1097","volume":"108","author":[{"given":"Kathryn","family":"Schmidt","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Spann","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Vanderbilit University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Qasim","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Western Ontario, London, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhal","family":"Izzy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Vanderbilit University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kymberly D.","family":"Watt","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/lt.24137","article-title":"Cardiovascular disease after liver transplantation: when, what, and who is at risk.","volume":"21","author":"Fussner","year":"2015","journal-title":"Liver Transpl"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/lt.23950","article-title":"High early cardiovascular mortality after liver transplantation.","volume":"20","author":"VanWagner","year":"2014","journal-title":"Liver Transpl"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/lt.25055","article-title":"Hospitalizations for cardiovascular disease after liver transplantation in the United States.","volume":"24","author":"Khurmi","year":"2018","journal-title":"Liver Transpl"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/lt.22468","article-title":"Cumulative risk of cardiovascular events after orthotopic liver transplantation.","volume":"18","author":"Albeldawi","year":"2012","journal-title":"Liver Transpl"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/lt.24738","article-title":"Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil.","volume":"23","author":"D\u2019Avola","year":"2017","journal-title":"Liver Transpl"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.30875","article-title":"Redefining cirrhotic cardiomyopathy for the modern era.","volume":"71","author":"Izzy","year":"2020","journal-title":"Hepatology"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"e1920294","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019.","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/lt.25067","article-title":"Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation.","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transpl"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/lt.25613","article-title":"The impact of coronary artery disease and statins on survival after liver transplantation.","volume":"25","author":"Patel","year":"2019","journal-title":"Liver Transpl"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/ajt.15706","article-title":"Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients.","volume":"20","author":"VanWagner","year":"2020","journal-title":"Am J Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1111\/ajt.17049","article-title":"Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations.","volume":"22","author":"Izzy","year":"2022","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 192 million participants.","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)32822-8","article-title":"The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report.","volume":"393","author":"Swinburn","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 2","key":"R15-20250604","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 annual data report: liver.","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2468-1253(19)30181-5","article-title":"Management of metabolic syndrome and cardiovascular risk after liver transplantation.","volume":"4","author":"Fatourou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review and guide to management.","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/lt.23508","article-title":"Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies.","volume":"18","author":"Madhwal","year":"2012","journal-title":"Liver Transpl"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/lt.21126","article-title":"Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events.","volume":"13","author":"Laryea","year":"2007","journal-title":"Liver Transpl"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"e14532","DOI":"10.1111\/ctr.14532","article-title":"A prospective longitudinal assessment of de novo metabolic syndrome after liver transplantation.","volume":"36","author":"Becchetti","year":"2022","journal-title":"Clin Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2009.717","article-title":"Non-alcoholic fatty liver disease in liver transplant recipients: another story of \u201cseed and soil\u201d.","volume":"105","author":"Dumortier","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1002\/hep.31647","article-title":"Cardiac risk assessment in liver transplant candidates: current controversies and future directions.","volume":"73","author":"Barman","year":"2021","journal-title":"Hepatology"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.29848","article-title":"Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy.","volume":"68","author":"Zamora-Valdes","year":"2018","journal-title":"Hepatology"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/j.1600-6143.2006.01391.x","article-title":"A randomized trial of exercise and dietary counseling after liver transplantation.","volume":"6","author":"Krasnoff","year":"2006","journal-title":"Am J Transplant"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1097\/TXD.0000000000001118","article-title":"Telehealth-delivered, cardioprotective diet and exercise program for liver transplant recipients: a randomized feasibility study.","volume":"7","author":"Hickman","year":"2021","journal-title":"Transplant Direct"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1432-2277.2006.00379.x","article-title":"Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial.","volume":"19","author":"Cassiman","year":"2006","journal-title":"Transpl Int"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/hep.31595","article-title":"Pharmacotherapy for weight loss in cirrhosis and liver transplantation: translating the data and underused potential.","volume":"73","author":"Brown","year":"2021","journal-title":"Hepatology"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/104454601750284117","article-title":"Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate.","volume":"11","author":"Lewis","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R31-20250604","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation.","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 30\u2009mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11695-014-1430-8","article-title":"Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery.","volume":"25","author":"Lazzati","year":"2015","journal-title":"Obes Surg"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/lt.25303","article-title":"Liver transplantation and bariatric surgery: timing and outcomes.","volume":"24","author":"Diwan","year":"2018","journal-title":"Liver Transpl"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/j.gastro.2017.01.035","article-title":"Clinical practice update: expert review on endoscopic bariatric therapies.","volume":"152","author":"Abu Dayyeh","year":"2017","journal-title":"Gastroenterology"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/lt.26074","article-title":"Efficacy and safety of endoscopic balloon placement for weight loss in patients with cirrhosis awaiting liver transplantation.","volume":"27","author":"Watt","year":"2021","journal-title":"Liver Transpl"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/1753-0407.12520","article-title":"Outcomes in patients with diabetes 10 years after liver transplantation.","volume":"9","author":"Ramos-Prol","year":"2017","journal-title":"J Diabetes"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.mayocp.2018.06.020","article-title":"New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: a machine learning approach.","volume":"93","author":"Bhat","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0000000000003647","article-title":"New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality.","volume":"106","author":"Vest","year":"2022","journal-title":"Transplantation"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"890359","DOI":"10.3389\/fcvm.2022.890359","article-title":"Pre-transplant type 2 diabetes mellitus is associated with higher graft failure and increased 5-year mortality after heart transplantation.","volume":"9","author":"Rivinius","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/TP.0000000000002757","article-title":"The impact of preexisting and post-transplant diabetes mellitus on outcomes following liver transplantation.","volume":"103","author":"Aravinthan","year":"2019","journal-title":"Transplantation"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2215\/CJN.09481209","article-title":"Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus.","volume":"5","author":"Chakkera","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation.","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1399-0012.2009.01194.x","article-title":"Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients.","volume":"24","author":"Luan","year":"2010","journal-title":"Clin Transplant"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/TP.0000000000003867","article-title":"Management of diabetes in candidates for liver transplantation and in transplant recipients.","volume":"106","author":"Brodosi","year":"2022","journal-title":"Transplantation"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function.","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial.","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"e012356","DOI":"10.1161\/JAHA.119.012356","article-title":"Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials.","volume":"8","author":"Giugliano","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.transproceed.2018.03.087","article-title":"Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study.","volume":"50","author":"Liou","year":"2018","journal-title":"Transplant Proc"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series.","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-019-0925-y","article-title":"Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.","volume":"18","author":"Ram","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances.","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels.","volume":"183","author":"D\u2019Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/lt.26331","article-title":"A meta-analysis and systematic review on the global prevalence, risk factors, and outcomes of coronary artery disease in liver transplantation recipients.","volume":"28","author":"Xiao","year":"2022","journal-title":"Liver Transpl"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT Extension Study.","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s40472-019-0232-2","article-title":"Hyperlipidemia and allograft rejection.","volume":"6","author":"Bagley","year":"2019","journal-title":"Curr Transplant Rep"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41598-020-79673-5","article-title":"An observational study on the effect of hypercholesterolemia developed after living donor liver transplantation on cardiac event and graft failure.","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"252564","DOI":"10.1155\/2015\/252564","article-title":"Effects of long-term statin therapy in coronary artery disease patients with or without chronic kidney disease.","volume":"2015","author":"Huang","year":"2015","journal-title":"Dis Markers"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"e014402","DOI":"10.1161\/JAHA.119.014402","article-title":"Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors.","volume":"9","author":"Miao","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis.","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/apt.17192","article-title":"Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.","volume":"56","author":"Becchetti","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2022.02.028","article-title":"Factors impacting survival in those transplanted for NASH cirrhosis: data from the NailNASH Consortium.","volume":"21","author":"Rinella","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"e003265","DOI":"10.1161\/CIRCHEARTFAILURE.116.003265","article-title":"Impact of statin use after heart transplantation: a meta-analysis.","volume":"9","author":"Vallakati","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/lt.26093","article-title":"Statin therapy and the incidence of thromboembolism and vascular events following liver transplantation.","volume":"27","author":"Frasco","year":"2021","journal-title":"Liver Transpl"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.111.081059","article-title":"Statins and the risk of cancer after heart transplantation.","volume":"126","author":"Fr\u00f6hlich","year":"2012","journal-title":"Circulation"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-018-38110-4","article-title":"Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients.","volume":"9","author":"Cho","year":"2019","journal-title":"Sci Rep"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/lt.21710","article-title":"Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.","volume":"15","author":"Almutairi","year":"2009","journal-title":"Liver Transpl"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","article-title":"Use of PCSK9 inhibitors in solid organ transplantation recipients.","volume":"2","author":"Warden","year":"2020","journal-title":"JACC Case Rep"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"704","DOI":"10.5604\/01.3001.0010.2709","article-title":"Fibrates for primary biliary cholangitis: what\u2019s all the hype?","volume":"16","author":"Levy","year":"2017","journal-title":"Ann Hepatol"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis.","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"802306","DOI":"10.3389\/fcvm.2021.802306","article-title":"The effects of fish oil on cardiovascular diseases: systematical evaluation and recent advance.","volume":"8","author":"Liao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R82-20250604","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3748\/wjg.v26.i18.2138","article-title":"Medical management of metabolic and cardiovascular complications after liver transplantation.","volume":"26","author":"Becchetti","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R83-20250604","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/lt.21952","article-title":"Posttransplant metabolic syndrome: an epidemic waiting to happen.","volume":"15","author":"Pagadala","year":"2009","journal-title":"Liver Transpl"},{"key":"R84-20250604","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"R85-20250604","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"R86-20250604","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/01.TP.0000158738.00927.65","article-title":"Mechanisms of hypertension after liver transplantation.","volume":"79","author":"Neal","year":"2005","journal-title":"Transplantation"},{"key":"R87-20250604","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.HYP.0000085195.38870.44","article-title":"Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.","volume":"42","author":"Nishiyama","year":"2003","journal-title":"Hypertension"},{"key":"R88-20250604","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1681\/ASN.V5111910","article-title":"Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation.","volume":"5","author":"Canzanello","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R89-20250604","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/lt.21588","article-title":"Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression.","volume":"14","author":"Bianchi","year":"2008","journal-title":"Liver Transpl"},{"key":"R90-20250604","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.22198","article-title":"Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events.","volume":"17","author":"Laish","year":"2011","journal-title":"Liver Transpl"},{"key":"R91-20250604","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"key":"R92-20250604","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1523-1755.1998.00852.x","article-title":"Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats.","volume":"53","author":"Cavarape","year":"1998","journal-title":"Kidney Int"},{"key":"R93-20250604","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrgastro.2015.172","article-title":"Keys to long-term care of the liver transplant recipient.","volume":"12","author":"Watt","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"R94-20250604","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ajt.15276","article-title":"OPTN\/SRTR 2017 annual data report: liver.","volume":"19","author":"Kim","year":"2019","journal-title":"Am J Transplant"},{"key":"R95-20250604","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R96-20250604","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.3748\/wjg.v22.i28.6416","article-title":"Metabolic complications in liver transplant recipients.","volume":"22","author":"Jim\u00e9nez-P\u00e9rez","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R97-20250604","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/lt.21442","article-title":"Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial.","volume":"14","author":"Galioto","year":"2008","journal-title":"Liver Transpl"},{"key":"R98-20250604","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.TP.0000116418.78963.DC","article-title":"Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation.","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"key":"R99-20250604","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/jlts.2000.9737","article-title":"Posttransplantation hypertension related to calcineurin inhibitors.","volume":"6","author":"Textor","year":"2000","journal-title":"Liver Transpl"},{"key":"R100-20250604","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients.","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R101-20250604","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1053-2498(98)00060-6","article-title":"A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.","volume":"18","author":"Taylor","year":"1999","journal-title":"J Heart Lung Transplant"},{"key":"R102-20250604","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.2042-7158.1996.tb03916.x","article-title":"The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs.","volume":"48","author":"Golbaekdal","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"R103-20250604","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1600-6143.2004.00427.x","article-title":"Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile.","volume":"4","author":"Artz","year":"2004","journal-title":"Am J Transplant"},{"key":"R104-20250604","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/01.TP.0000140848.05002.B8","article-title":"The burden of acute renal failure in nonrenal solid organ transplantation.","volume":"78","author":"Wyatt","year":"2004","journal-title":"Transplantation"},{"key":"R105-20250604","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1159\/000502523","article-title":"Acute kidney injury and long-term risk for cardiovascular events in patients after kidney transplantation.","volume":"44","author":"Rahamimov","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"R106-20250604","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3390\/jcm11113100","article-title":"Excess risk of major adverse cardiovascular and kidney events after acute kidney injury following living donor liver transplantation.","volume":"11","author":"Chan","year":"2022","journal-title":"J Clin Med"},{"key":"R107-20250604","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/TP.0000000000003306","article-title":"Prediction of perioperative cardiovascular events in liver transplantation.","volume":"105","author":"Koshy","year":"2021","journal-title":"Transplantation"},{"key":"R108-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN108671","article-title":"Acute kidney injury (AKI) outcome, a predictor of long-term major adverse cardiovascular events (MACE).","volume":"85","author":"Omotoso","year":"2016","journal-title":"Clin Nephrol"},{"key":"R109-20250604","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12872-019-01309-y","article-title":"Progression of endothelial dysfunction, atherosclerosis, and arterial stiffness in stable kidney transplant patients: a pilot study.","volume":"20","author":"Junarta","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"R110-20250604","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/lt.26425","article-title":"Glomerular filtration rate early after liver transplantation independently predicts atherosclerotic events.","volume":"28","author":"Hassouneh","year":"2022","journal-title":"Liver Transpl"},{"key":"R111-20250604","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/ajt.13779","article-title":"Factors associated with major adverse cardiovascular events after liver transplantation among a national sample.","volume":"16","author":"VanWagner","year":"2016","journal-title":"Am J Transplant"},{"key":"R112-20250604","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jac5.1387","article-title":"Transplant clinical pharmacy services improve cardiovascular risk factor management and control in veteran organ transplant recipients.","volume":"4","author":"Elmaasarani","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"key":"R113-20250604","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1399-0012.2004.00171.x","article-title":"Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.","volume":"18","author":"Wong","year":"2004","journal-title":"Clin Transplant"},{"key":"R114-20250604","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ctr.12353","article-title":"Renal function preservation with the mTOR inhibitor, everolimus, after lung transplant.","volume":"28","author":"Schneer","year":"2014","journal-title":"Clin Transplant"},{"key":"R115-20250604","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1111\/ajt.13790","article-title":"Protecting the kidney in liver transplant candidates: practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice.","volume":"16","author":"O\u2019Leary","year":"2016","journal-title":"Am J Transplant"},{"key":"R116-20250604","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/endrev\/bnaa030","article-title":"Metabolic consequences of solid organ transplantation.","volume":"42","author":"Bhat","year":"2021","journal-title":"Endocr Rev"},{"key":"R117-20250604","doi-asserted-by":"crossref","first-page":"101683","DOI":"10.1016\/j.bpg.2020.101683","article-title":"Cardiovascular and metabolic disease in the liver transplant recipient.","volume":"46-47","author":"Kim","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R118-20250604","doi-asserted-by":"crossref","first-page":"101762","DOI":"10.1016\/j.bpg.2021.101762","article-title":"Adverse effects of immunosuppression after liver transplantation.","volume":"54-55","author":"Noble","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R119-20250604","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/egh.13.19","article-title":"Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review.","volume":"7","author":"Oliveira","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R120-20250604","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/lt.21396","article-title":"Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials.","volume":"14","author":"Segev","year":"2008","journal-title":"Liver Transpl"},{"key":"R121-20250604","first-page":"CD013203","article-title":"Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis.","volume":"1","author":"Best","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R122-20250604","first-page":"CD007606","article-title":"Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.","volume":"4","author":"Fairfield","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R123-20250604","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/lt.21854","article-title":"A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.","volume":"15","author":"Otero","year":"2009","journal-title":"Liver Transpl"},{"key":"R124-20250604","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1097\/TP.0000000000001739","article-title":"Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study.","volume":"101","author":"Holdaas","year":"2017","journal-title":"Transplantation"},{"key":"R125-20250604","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/TP.0000000000001693","article-title":"mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis.","volume":"102","author":"Kurdi","year":"2018","journal-title":"Transplantation"},{"key":"R126-20250604","doi-asserted-by":"crossref","first-page":"845438","DOI":"10.1155\/2014\/845438","article-title":"The role of mTOR inhibitors in liver transplantation: reviewing the evidence.","volume":"2014","author":"Klintmalm","year":"2014","journal-title":"J Transplant"},{"key":"R127-20250604","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1432-2277.2004.00067.x","article-title":"Weight gain and obesity after liver transplantation.","volume":"18","author":"Richards","year":"2005","journal-title":"Transpl Int"},{"key":"R128-20250604","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.transproceed.2011.07.011","article-title":"Arterial hypertension in liver transplant recipients.","volume":"43","author":"Hryniewiecka","year":"2011","journal-title":"Transplant Proc"},{"key":"R129-20250604","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1600-6143.2005.00808.x","article-title":"A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.","volume":"5","author":"Lucey","year":"2005","journal-title":"Am J Transplant"},{"key":"R130-20250604","first-page":"CD005161","article-title":"Cyclosporin versus tacrolimus for liver transplanted patients.","volume":"2006","author":"Haddad","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R131-20250604","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/TP.0000000000001913","article-title":"Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study.","volume":"101","author":"Charlton","year":"2017","journal-title":"Transplantation"},{"key":"R132-20250604","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/lt.20442","article-title":"Tobacco use by liver transplant recipients: grappling with a smoking gun.","volume":"11","author":"Mu\u00f1oz","year":"2005","journal-title":"Liver Transpl"},{"key":"R133-20250604","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/jlts.2002.34150","article-title":"Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation.","volume":"8","author":"Pungpapong","year":"2002","journal-title":"Liver Transpl"},{"key":"R134-20250604","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/lt.25417","article-title":"Marijuana consumption in liver transplant recipients.","volume":"25","author":"Serrano Rodriguez","year":"2019","journal-title":"Liver Transpl"},{"key":"R135-20250604","doi-asserted-by":"crossref","first-page":"e1288","DOI":"10.1097\/TXD.0000000000001288","article-title":"Poor practitioner adherence to clinical tobacco use guidelines in liver transplant recipients.","volume":"8","author":"Harrington","year":"2022","journal-title":"Transplant Direct"},{"key":"R136-20250604","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.mcna.2004.07.011","article-title":"Pharmacotherapy of tobacco dependence.","volume":"88","author":"Talwar","year":"2004","journal-title":"Med Clin North Am"},{"key":"R138-20250604","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jamainternmed.2020.4055","article-title":"Efficacy of smartphone applications for smoking cessation: a randomized clinical trial.","volume":"180","author":"Bricker","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R139-20250604","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"R140-20250604","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psym.2014.09.006","article-title":"Risk factors for alcohol relapse following orthotopic liver transplantation: a systematic review.","volume":"56","author":"Rustad","year":"2015","journal-title":"Psychosomatics"},{"key":"R141-20250604","doi-asserted-by":"crossref","first-page":"101685","DOI":"10.1016\/j.bpg.2020.101685","article-title":"Alcohol and other substance use after liver transplant.","volume":"46-47","author":"Winder","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R142-20250604","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/acer.13603","article-title":"Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study.","volume":"42","author":"DeMartini","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"R143-20250604","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jceh.2019.05.004","article-title":"Preventive strategies for nonalcoholic fatty liver disease after liver transplantation.","volume":"9","author":"Choudhary","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"R144-20250604","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.transproceed.2019.03.087","article-title":"Physical condition, glycemia, liver function, and quality of life in liver transplant recipients after a 12-month supervised exercise program.","volume":"51","author":"Totti","year":"2019","journal-title":"Transplant Proc"},{"key":"R145-20250604","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/152692480701700410","article-title":"Community-based weight management in long-term heart transplant recipients: a pilot study.","volume":"17","author":"Salyer","year":"2007","journal-title":"Prog Transplant"},{"key":"R146-20250604","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jhn.12874","article-title":"Diet and physical activity after liver transplant: a qualitative study of barriers and facilitators to following advice.","volume":"34","author":"Spillman","year":"2021","journal-title":"J Hum Nutr Diet"},{"key":"R147-20250604","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/lt.26000","article-title":"Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria.","volume":"27","author":"Izzy","year":"2021","journal-title":"Liver Transpl"},{"key":"R148-20250604","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/lt.26460","article-title":"Cirrhotic cardiomyopathy: appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes.","volume":"28","author":"Spann","year":"2022","journal-title":"Liver Transpl"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:05:54Z","timestamp":1749060354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":146,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004875","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}